Evolution from active surveillance to focal therapy in the management of prostate cancer

Future Oncology

Volumn 7, Issue 6, 2011, Pages 775-787

  Lindner, Uri ^a,b   Lawrentschuk, Nathan ^c   Schatloff, Oscar ^d   Trachtenberg, John ^a   Lindner, Arie ^d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

active surveillance; cryotherapy; focal therapy; HIFU; laser; MRI; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACTIVE SURVEILLANCE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SURVIVAL; CANCER THERAPY; CELL DEATH; CLINICAL EFFECTIVENESS; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED ULTRASONOGRAPHY; CRYOTHERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; ECHOGRAPHY; ELASTOGRAPHY; FOCAL LASER ABLATION; FOCAL THERAPY; FOLLOW UP; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LASER SURGERY; MECHANICAL STRESS; MEDICAL RECORD REVIEW; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL FUNCTION; SURVIVAL RATE; SURVIVAL TIME; THERMAL INJURY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR ABLATION; TUMOR BIOPSY; TUMOR VOLUME;

CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; HUMANS; MALE; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 79959398516     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.51     Document Type: Review

References (117)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010 CA Cancer J. Clin. 60(5), 277-300 (2010)
2. Welch HG, Albertsen PC: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005 J. Natl Cancer Inst. 101(19), 1325-1329 (2009)
3. Shao YH, Demissie K, Shih W et al.: Contemporary risk profile of prostate cancer in the United States. J. Natl Cancer Inst. 101(18), 1280-1283 (2009)
4. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends in low risk prostate cancer: risk assessment and treatment. J. Urol. 178(3 Pt 2), S14-S19 (2007) (Pubitemid 47224952)
5. Wei JT, Dunn RL, Sandler HM et al.: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J. Clin. Oncol. 20(2), 557-566 (2002) (Pubitemid 34072540)
6. Sanda MG, Dunn RL, Michalski J et al.: Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358(12), 1250-1261 (2008) (Pubitemid 351439226)
7. Bill-Axelson A, Holmberg L, Filen F et al.: Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J. Natl Cancer Inst. 100(16), 1144-1154 (2008)
8. Johansson JE, Andren O, Andersson SO et al.: Natural history of early, localized prostate cancer. JAMA 291(22), 2713-2719 (2004) (Pubitemid 38725420)
9. Schroder FH, Hugosson J, Roobol MJ et al.: Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320-1328 (2009)
10. Hugosson J, Carlsson S, Aus G et al.: Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 11(8), 725-732 (2010)
11. Draisma G, Etzioni R, Tsodikov A et al.: Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J. Natl Cancer Inst. 101(6), 374-383 (2009)
12. Choo R, Klotz L, Danjoux C et al.: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J. Urol. 167(4), 1664-1669 (2002) (Pubitemid 34240696)
13. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR: What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J. Urol. 180(4), 1330-1334; discussion 1334-1335 (2008)
14. Vogl TJ, Straub R, Eichler K, Sollner O, Mack MG: Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy - local tumor control rate and survival data. Radiology 230(2), 450-458 (2004) (Pubitemid 38133806)
15. Gough-Palmer AL, Gedroyc WM: Laser ablation of hepatocellular carcinoma - a review. World J. Gastroenterol. 14(47), 7170-7174 (2008)
16. Pacella CM, Francica G, Di Lascio FM et al.: Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. J. Clin. Oncol. 27(16), 2615-2621 (2009)
17. Dick EA, Joarder R, De Jode MG, Wragg P, Vale JA, Gedroyc WM: Magnetic resonance imaging-guided laser thermal ablation of renal tumours. BJU Int. 90(9), 814-822 (2002) (Pubitemid 36693611)
18. Lindner U, Lawrentschuk N, Trachtenberg J: Image guidance for focal therapy of prostate cancer. World J. Urol. 28(6), 727-734 (2010)
19. Lawrentschuk N, Klotz L: Active surveillance for low-risk prostate cancer - an update. Nat. Rev. Urol. DOI:101038/nrurol.201150 (2011) (Epub ahead of print)
20. Liu W, Laitinen S, Khan S et al.: Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15(5), 559-565 (2009)
21. Ohori M, Eastham JA, Koh H et al.: Is focal therapy reasonable in patients with early stage prostate cancer (CaP) - an analysis of radical prostatectomy (RP) specimens. J. Urol. 175(Suppl. 4), 507-507 (2006)
22. Ahmed HU: The index lesion and the origin of prostate cancer. N. Engl. J. Med. 361(17), 1704-1706 (2009)
23. Ward JF, Jones JS: Classification system: organ preserving treatment for prostate cancer. Urology 75(6), 1258-1260 (2010)
24. Ward JF, Nakanishi H, Pisters L, Babaian RJ, Troncoso P: Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int. 104(4), 490-497 (2009)
25. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28(1), 126-131 (2010)
26. Hayes JH, Ollendorf DA, Pearson SD et al.: Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 304(21), 2373-2380 (2010)
27. Cooperberg MR, Cowan JE, Hilton JF et al.: Outcomes of active surveillance for men with intermediate-risk prostate cancer. J. Clin. Oncol. 29(2), 228-234 (2010)
28. Ramsey SD, Zeliadt SB, Fedorenko CR et al.: Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J. Urol 29(1), 3-9 (2010)
29. van den Bergh RC, Roemeling S, Roobol MJ et al.: Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur. Urol. 55(1), 1-8 (2009)
30. Fang F, Keating NL, Mucci LA et al.: Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J. Natl Cancer Inst. 102(5), 307-314 (2010)
31. Johnson TV, Garlow SJ, Brawley OW, Master VA: Peak window of suicides occurs within the first month of diagnosis: implications for clinical oncology. Psychooncology DOI: 101002/pon.1905 (2011) (Epub ahead of print)
32. Thompson IM, Klotz L: Active surveillance for prostate cancer. JAMA 304(21), 2411-2412 (2010)
33. Klotz L: Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol. Oncol. 24(1), 46-50 (2006). (Pubitemid 43097357)
34. Dall'era MA, Cowan JE, Simko J et al.: Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int 107(2), 338 (2011)
35. Bacon CG, Giovannucci E, Testa M, Kawachi I: The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J. Urol. 166(5), 1804-1810 (2001)
36. Galbraith ME, Ramirez JM, Pedro LW: Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol. Nurs. Forum 28(3), 551-560 (2001)
37. Litwin MS, Lubeck DP, Spitalny GM, Henning JM, Carroll PR: Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer 95(1), 54-60 (2002) (Pubitemid 34743482)
38. Arredondo SA, Downs TM, Lubeck DP et al.: Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J. Urol. 172(5 Pt 1), 1830-1834 (2004) (Pubitemid 39363067)
39. Steineck G, Helgesen F, Adolfsson J et al.: Quality of life after radical prostatectomy or watchful waiting. N. Engl. J. Med. 347(11), 790-796 (2002) (Pubitemid 34988337)
40. van den Bergh RC, Essink-Bot ML, Roobol MJ, Schroder FH, Bangma CH, Steyerberg EW: Do anxiety and distress increase during active surveillance for low risk prostate cancer? J. Urol. 183(5), 1786-1791 (2010)
41. Turkbey B, Pinto PA, Choyke PL: Imaging techniques for prostate cancer: implications for focal therapy. Nat. Rev. Urol. 6(4), 191-203 (2009)
42. Watanabe H, Igari D, Tanahashi Y, Harada K, Saitoh M: Transrectal ultrasonotomography of the prostate. J. Urol. 114(5), 734-739 (1975)
43. Ellis DS, Manny TB Jr, Rewcastle JC: Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology 70(Suppl. 6), 9-15 (2007)
44. Lambert EH, Bolte K, Masson P, Katz AE: Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 69(6), 1117-1120 (2007) (Pubitemid 46891597)
45. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J: Male lumpectomy: focal therapy for prostate cancer using cryoablation. Urology 70(Suppl. 6), 16-21 (2007)
46. Bahn DK, Silverman P, Lee F Sr, Badalament R, Bahn ED, Rewcastle JC: Focal prostate cryoablation: initial results show cancer control and potency preservation. J. Endourol. 20(9), 688-692 (2006) (Pubitemid 46140997)
47. Gowardhan B, Greene D: Cryotherapy for the prostate: an in vitro and clinical study of two new developments; advanced cryoneedles and a temperature monitoring system. BJU Int. 100(2), 295-302 (2007) (Pubitemid 47036582)
48. Steed J, Saliken JC, Donnelly BJ, Ali-Ridha NH: Correlation between thermosensor temperature and transrectal ultrasonography during prostate cryoablation. Can. Assoc. Radiol. J. 48(3), 186-190 (1997) (Pubitemid 27339219)
49. Zlotta AR, Djavan B, Matos C et al.: Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br. J. Urol. 81(2), 265-275 (1998)
50. Mitterberger M, Horninger W, Pelzer A et al.: A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection. Prostate 67(14), 1537-1542 (2007) (Pubitemid 47536152)
51. Wink M, Frauscher F, Cosgrove D et al.: Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project. Eur. Urol. 54(5), 982-992 (2008)
52. Atri M, Gertner MR, Haider MA, Weersink RA, Trachtenberg J: Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer. Can. Urol. Assoc. J. 3(2), 125-130 (2009)
53. Hu B, Chen L, Li J, Huang J: Contrast-enhanced ultrasonography evaluation of radiofrequency ablation of the prostate: a canine model. J. Endourol. 24(1), 89-93 (2010)
54. Lindner U, Weersink RA, Haider MA et al.: Image guided photothermal focal therapy for localized prostate cancer: Phase I trial. J. Urol. 182(4), 1371-1377 (2009)
55. Konig K, Scheipers U, Pesavento A, Lorenz A, Ermert H, Senge T: Initial experiences with real-time elastography guided biopsies of the prostate. J. Urol. 174(1), 115-117 (2005) (Pubitemid 40825688)
56. Pallwein L, Mitterberger M, Struve P et al.: Real-time elastography for detecting prostate cancer: preliminary experience. BJU Int. 100(1), 42-46 (2007) (Pubitemid 46878542)
57. Miyagawa T, Tsutsumi M, Matsumura T et al.: Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images. Jpn J. Clin. Oncol. 39(6), 394-398 (2009)
58. Sumura M, Shigeno K, Hyuga T, Yoneda T, Shiina H, Igawa M: Initial evaluation of prostate cancer with real-time elastography based on step-section pathologic analysis after radical prostatectomy: a preliminary study. Int. J. Urol. 14(9), 811-816 (2007) (Pubitemid 47313273)
59. Righetti R, Kallel F, Stafford RJ et al.: Elastographic characterization of HIFU-induced lesions in canine livers. Ultrasound Med. Biol. 25(7), 1099-1113 (1999) (Pubitemid 29408504)
60. Varghese T, Techavipoo U, Liu W et al.: Elastographic measurement of the area and volume of thermal lesions resulting from radiofrequency ablation: pathologic correlation. AJR Am. J. Roentgenol. 181(3), 701-707 (2003) (Pubitemid 37021838)
61. Steyn JH, Smith FW: Nuclear magnetic resonance imaging of the prostate. Br. J. Urol. 54(6), 726-728 (1982) (Pubitemid 13179610)
62. Haider MA, van der Kwast TH, Tanguay J et al.: Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am. J. Roentgenol. 189(2), 323-328 (2007) (Pubitemid 47195916)
63. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K: Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J. Magn. Reson. Imaging 31(3), 625-631 (2010).
64. Zhang J, Hricak H, Shukla-Dave A et al.: Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology 253(2), 425-434 (2009)
65. Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA: Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J. Magn. Reson. Imaging 30(2), 327-334 (2009)
66. Zakian KL, Sircar K, Hricak H et al.: Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234(3), 804-814 (2005) (Pubitemid 40250824)
67. Groenendaal G, Moman MR, Korporaal JG et al.: Validation of functional imaging with pathology for tumor delineation in the prostate. Radiother. Oncol. 94(2), 145-150 (2010)
68. Raz O, Haider MA, Davidson SR et al.: Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur. Urol. 58(1), 173-177 (2010)
69. Schwarzmaier HJ, Eickmeyer F, von Tempelhoff W et al.: MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients. Eur. J. Radiol. 59(2), 208-215 (2006) (Pubitemid 44093175)
70. Dickinson L, Ahmed HU, Allen C et al.: Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur. Urol. 59(4), 477-494 (2011)
71. Djavan B, Zlotta AR, Susani M et al.: Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination. Urology 50(6), 986-992; discussion 992-983 (1997)
72. Larson BT, Collins JM, Huidobro C, Corica A, Vallejo S, Bostwick DG: Gadolinium-enhanced MRI in the evaluation of minimally invasive treatments of the prostate: correlation with histopathologic findings. Urology 62(5), 900-904 (2003) (Pubitemid 37421239)
73. Lindner U, Lawrentschuk N, Weersink RA et al.: Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur. Urol. 57(6), 1111-1114 (2010)
74. Hushek SG, Martin AJ, Steckner M, Bosak E, Debbins J, Kucharzyk W: MR systems for MRI-guided interventions. J. Magn. Reson. Imaging 27(2), 253-266 (2008) (Pubitemid 351214035)
75. Pech M, Wieners G, Freund T et al.: MR-guided interstitial laser thermotherapy of colorectal liver metastases: efficiency, safety and patient survival. Eur. J. Med. Res. 12(4), 161-168 (2007) (Pubitemid 46746005)
76. Zangos S, Eichler K, Thalhammer A et al.: MR-guided interventions of the prostate gland. Minim. Invasive Ther. Allied Technol. 16(4), 222-229 (2007) (Pubitemid 47343469)
77. Hambrock T, Somford DM, Hoeks C et al.: Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J. Urol. 183(2), 520-527 (2010)
78. Raz O, Haider MA, Davidson SR et al.: Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur. Urol. 58(1), 173-177 (2010)
79. Moche M, Trampel R, Kahn T, Busse H: Navigation concepts for MR image-guided interventions. J. Magn. Reson. Imaging 27(2), 276-291 (2008) (Pubitemid 351222536)
80. Soanes WA, Gonder MJ: Use of cryosurgery in prostatic cancer. J. Urol. 99(6), 793-797 (1968)
81. Gonder MJ, Soanes WA, Shulman S: Cryosurgical treatment of the prostate. Invest. Urol. 3(4), 372-378 (1966)
82. Gonder MJ, Soanes WA, Smith V: Experimental prostate cryosurgery. Invest. Urol. 1, 610-619 (1964)
83. Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R: Focal "nerve-sparing" cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology 60(1), 109-114 (2002) (Pubitemid 34722957)
84. Pisters LL, Dinney CP, Pettaway CA et al.: A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J. Urol. 161(2), 509-514 (1999)
85. Grampsas SA, Miller GJ, Crawford ED: Salvage radical prostatectomy after failed transperineal cryotherapy: histologic findings from prostate whole-mount specimens correlated with intraoperative transrectal ultrasound images. Urology 45(6), 936-941 (1995)
86. Bailey MR, Khokhlova VA, Sapozhnikov OA, Kargl SG, Crum LA: Physical mechanisms of the therapeutic effect of ultrasound. Acoust. Phys. 49(4), 369-388 (2008)
87. Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M: Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 55(15), 3346-3351 (1995)
88. Beerlage HP, Thuroff S, Debruyne FM, Chaussy C, de la Rosette JJ: Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma. Urology 54(2), 273-277 (1999) (Pubitemid 29367251)
89. Ahmed HU, Freeman A, Kirkham A et al.: Focal therapy for localized prostate cancer: a Phase I/II trial. J. Urol. 185(4), 1246-1254 (2011)
90. De Senneville BD, Mougenot C, Moonen CT: Real-time adaptive methods for treatment of mobile organs by MRI-controlled high-intensity focused ultrasound. Magn. Reson. Med. 57(2), 319-330 (2007) (Pubitemid 46214535)
91. de Senneville BD, Mougenot C, Quesson B, Dragonu I, Grenier N, Moonen CT: MR thermometry for monitoring tumor ablation. Eur. Radiol. 17(9), 2401-2410 (2007) (Pubitemid 47288279)
92. Chopra R, Tang K, Burtnyk M et al.: Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback. Phys. Med. Biol. 54(9), 2615-2633 (2009)
93. Costello AJ, Johnson DE, Bolton DM: Nd:YAG laser ablation of the prostate as a treatment for benign prostatic hypertrophy. Lasers Surg. Med. 12(2), 121-124 (1992)
94. McNicholas TA, Carter SS, Wickham JE, O'Donoghue EP: YAG laser treatment of early carcinoma of the prostate. Br. J. Urol. 61(3), 239-243 (1988) (Pubitemid 18085424)
95. Bown SG: Phototherapy in tumors. World J. Surg. 7(6), 700-709 (1983)
96. Beisland HO, Stranden E: Rectal temperature monitoring during neodymion-YAG laser irradiation for prostatic carcinoma. Urol. Res. 12(5), 257-259 (1984) (Pubitemid 15206871)
97. Amin Z, Lees WR, Bown SG: Technical note: interstitial laser photocoagulation for the treatment of prostatic cancer. Br. J. Radiol. 66(791), 1044-1047 (1993)
98. Garcea G, Lloyd TD, Aylott C, Maddern G, Berry DP: The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours. Eur. J. Cancer 39(15), 2150-2164 (2003) (Pubitemid 37297739)
99. Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG: Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology 114(1), 162-169 (2007) (Pubitemid 46014287)
100. Eggener SE, Scardino PT, Carroll PR et al.: Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J. Urol. 178(6), 2260-2267 (2007) (Pubitemid 350052204)
101. Onik G: The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review. Technol. Cancer Res. Treat. 3(4), 365-370 (2004) (Pubitemid 39096608)
102. Spiess PE, Given R, Mouraviev V, Jones JS: 1639 Achieving the "Trifecta" using focal cryotherapy for localized prostate cancer: COLD registery data. J. Urol. 185(Suppl. 4), E658 (2011)
103. Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S: Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J. Clin. Oncol. 38(3), 192-199 (2008) (Pubitemid 351419743)
104. Iczkowski KA, Hossain D, Torkko KC et al.: Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology 71(6), 1166-1171 (2008)
105. Grover S, Srivastava A, Tan G et al.: Clinicopathological strategies to identify contralateral prostate cancer involvement in potential candidates for focal therapy. Int. J. Surg. Pathol. 18(6), 499-507 (2010)
106. Abdollah F, Scattoni V, Raber M et al.: The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU Int. DOI: 101111/j.1464-410X.201009876x (2010) (Epub ahead of print)
107. Onik G, Barzell W: Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol. Oncol. 26(5), 506-510 (2008)
108. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28(1), 126-131 (2009)
109. van den Bergh RC, Roemeling S, Roobol MJ et al.: Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur. Urol. 55(1), 1-8 (2009)
110. Dall'Era MA, Konety BR, Cowan JE et al.: Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112(12), 2664-2670 (2008) (Pubitemid 351969209)
111. Kakehi Y, Kamoto T, Shiraishi T et al.: Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J. Clin. Oncol. 38(2), 122-128 (2008) (Pubitemid 351337956)
112. Carter HB, Kettermann A, Warlick C et al.: Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J. Urol. 178(6), 2359-2364; discussion 2364-2355 (2007)
113. Roemeling S, Roobol MJ, de Vries SH et al.: Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur. Urol. 51(5), 1244-1250; discussion 1251 (2007)
114. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M: Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur. Urol. 58(6), 831-835 (2010)
115. Hardie C, Parker C, Norman A et al.: Early outcomes of active surveillance for localized prostate cancer. BJU Int. 95(7), 956-960 (2005) (Pubitemid 40655686)
116. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT: An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J. Urol. 171(4), 1520-1524 (2004) (Pubitemid 38365409)
117. Lindner U, Trachtenberg J, Lawrentschuk N: Focal therapy in prostate cancer: modalitie, findings and future considerations. Nat. Rev. Urol. 7(10), 562-571 (2010).